Acral Erythema and Hydroxyurea
Authors: FRANCES SANDLER SILVER
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 May 1983Acral Erythema and HydroxyureaFRANCES SANDLER SILVER, M.D., LUIS R. ESPINOZA, M.D., ROBERT C. HARTMANN, M.D.FRANCES SANDLER SILVER, M.D.Search for more papers by this author, LUIS R. ESPINOZA, M.D.Search for more papers by this author, ROBERT C. HARTMANN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-5-675_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Acral erythema or Raynaud's phenomenon has been described in patients on various chemotherapeutic regimens, notably those including bleomycin and vinblastine (1-3). An adjuvant role for cispiatin and for smoking has also been suggested (1). Burgdorf and associates (4) have described a patient with acute myeloid leukemia who developed acral erythema while on a chemotherapeutic regimen that did not include bleomycin or vinblastine but consisted of cytarabine, doxorubicin, and vincristine (4). We recently saw a patient who developed acral erythema but whose only chemotherapeutic drug was hydroxyurea and whose symptoms recurred with a second use of the drug....References1. VOGELZANGBOSLJOHNSONKENNEDY NGKB. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288-92. LinkGoogle Scholar2. DORSK B. Raynaud's phenomenon and cancer chemotherapy [Letter]. Ann Intern Med. 1981;95:652-3. LinkGoogle Scholar3. GRAUGRAUMILLÁESTAPÉMULET JMAJM. Cancer chemotherapy and Raynaud's phenomenon [Letter]. Ann Intern Med. 1983;98:258. LinkGoogle Scholar4. BURGDORFGILMOREGANICK WWR. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97:61-2. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of South Florida College of Medicine Tampa, FL 33612 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCapecitabine and hand–foot syndromeToxic erythema of chemotherapy: A useful clinical termHand-foot syndrome with docetaxel: a five-case seriesCHEMOTHERAPY-INDUCED ACRAL ERYTHEMA IN A PEDIATRIC PATIENT WITH ACUTE MONOBLASTIC LEUKEMIAPalmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreVascular Toxicity of Antineoplastic AgentsPalmar-plantar erythrodysesthesiaClofarabine-induced Acral Erythema During the Treatment of Patients with Myelodysplasia and Acute Leukemia: Report of Two CasesMuco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemiaHydroxyurea-induced skin disease mimicking the baboon syndromeMucocutaneous reactions to chemotherapyCutaneous Ulcers Associated with Hydroxyurea Therapy in Myeloproliferative DisordersAcral erythema induced by chemotherapy with cisplatinHigh Incidence of Chemotherapy-Induced Acral Erythema in Female Patients with non-Hodgkin's Lymphoma Treated with the Vacop-B RegimenHydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyureaHydroxyurea-induced dermatomyositis-like eruptionThree Cases of Chemotherapy-induced Acral ErythemaThe cutaneous histopathology of chemotherapeutic reactionsChemotherapy-induced acral erythemaSkin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapyAcral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusionsTreatment of polycythemia vera with hydroxyureaThe inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY) 1 May 1983Volume 98, Issue 5_Part_1Page: 675-675KeywordsAcute myeloid leukemiaDrugsErythemaRaynaud syndrome Issue Published: 1 May 1983 PDF downloadLoading ...